What is the lead time for orders?

Peak season lead time is one month, while off-season lead time is within 15 workdays.

How is the product sterilized?

The stapler is sterilized using Ethylene Oxide.

What is the standard packaging?

The product is packed in a Carton Box.

Reliable Circumcision Stapler for Effective Phimosis Treatment in Males

Name: Reliable Circumcision Stapler for Effective Phimosis Treatment in Males
Brand: Contiwin Co., Ltd
SKU: 2322274385

Shanghai, ChinaContiwin Co., Ltd

US$11.00-20.00

100 Pieces

Product specifications

Specifications

Sample price:US$30.00/piece.Request sample

Product profile

Customization

Available

Type

Scalpel

Material

Stainless Steel

Model NO.

A, B, C, D

Quality Guarantee Period

2 Years

Group

Adlut, Children

Application

Anorectal, Urology

Feature

Disposable

Certification

CE, ISO13485

Sterilization

Ethylene Oxide

Transport Package

Carton Box

Specification

15*5*10

Trademark

OEM ODM

Origin

China

HS Code

9018322000

Production Capacity

10000000pieces/Year

Key features

Single-Use Design: Avoids cross-infection during surgery with disposable construction.

Minimal Tissue Injury: Causes less damage to tissue compared to traditional methods.

Faster Recovery: Enables quicker patient recovery with a nice cutting edge.

Shorter Operative Time: Reduces surgery duration and lowers blood loss volume.

Solves Edema and Pain: Eliminates foreskin edema and pain caused by compression.

CE Certified: Meets European safety standards for medical devices.

2-Year Quality Guarantee: Provides a comprehensive 2-year quality assurance period.

OEM/ODM Support: Offers customized manufacturing services for branding.

Company profile

Contiwin Co., Ltd

Shanghai, China

Business Type: Manufacturer/FactoryAverage Response Time: ≤0.28h

AI-Powered supplier vetting

SummaryContiwin Co., Ltd is a China-based limited company established in 2020 and identified as a trading company, with an export license and export sales share of 71%–90%. The supplier reports more than 10 production lines, 31–40 quality-control staff, and stated output for hemodialyser flux and A-V blood lines, but other data identifies only three total employees and zero cooperative suppliers, creating internal consistency concerns. Lead times are within 15 workdays in both peak and off-season periods. Overseas infrastructure is limited to participation in an offline medical equipment exhibition; no overseas warehouses, showrooms, agents, branches, or service countries are reported. Quality-system evidence is incomplete: test equipment is listed as zero, complaint procedures and service corrective-action procedures are absent, and quality assurance and traceability status are unknown. No new products, ODM, OEM for popular brands, or SDK are reported. Financial-capacity records are present for multiple years,...

Supplier typeThe supplier is identified as Contiwin Co., Ltd, a China-based limited company established in 2020 and classified as a trading company. Its stated business scope includes medical instruments, production, and import-export services, while no larger-company affiliation is reported.

CertificationsThe supplier explicitly reports holding a valid import and export license. No other certification, quality-system certificate, or product certification is identified in the provided slices, so the assessment is limited to export licensing.

After-Sales capabilityThe supplier reports no written customer-complaint procedures or records, no written service-capability assessment or corrective-action procedures, and no overseas warehouses, showrooms, agents, branches, or service countries. It has participated in one offline medical equipment exhibition and reports lead times within 15 workdays, but these do not establish strong after-sales support.

R&D capabilityThe supplier reports one R&D engineer whose stated responsibility is providing samples to customer requirements. It reports no new products in the past year, no ODM service, no OEM for popular brands, and no available SDK, indicating limited demonstrated innovation capability.